NR3C2 and thyroid cancer: A recent study has shown the genetic variant–drug interaction in drug treatment in thyroid cancer: Genetic variant rs1512325, located in nuclear receptor subfamily 3 group C member 2 (NR3C2), is associated with remission of thyroid cancer, and the efficacy of venlafaxine treatment is modified by altering serum thyroid-stimulating hormone (TSH) concentrations according to the patients with rs1512325 polymorphism [6].